CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A clinical trial testing the safety and tolerability of an experimental HIV vaccine developed by Merck Research Laboratories will get under way in May at the University of California, Davis, School of Medicine and Medical Center. The UC Davis study is part of a multisite clinical trial and will enroll 10 to 20 volunteers, with a total of 273 people enrolled nationwide. The Phase I trial will study the safety and tolerability of a DNA-based vaccine that Merck hopes will help prevent HIV infections. The vaccine uses three synthetic versions of key HIV genes--Gag, Pol, and Nef--to stimulate an immune system defense against the virus. "This vaccine is an expanded version of the previous candidate vaccines designed to elicit a broader, and hopefully, more effective response to HIV," said David Asmuth, an assistant professor at UC Davis. "The previous versions were generally well tolerated in volunteers tested, and their effect on the immune system is still being tested. Merck Research Laboratories has made a commitment to developing an effective vaccine against HIV and we are grateful to be invited to participate in this important cause."
From our Sponsors
Most Popular
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Latest Stories
Advocate Channel
HealthAdvocate Channel
WomenMuslim Women Athletes Condemn Hijab Bans, Fight For Inclusive Clothing in Sports
January 17 2023 11:45 AM
Advocate Channel
Police